Jacqueline Cloos, PhD, Amsterdam UMC, Amsterdam, The Netherlands, shares some insights into the importance of considering oligoclonality when assessing measurable residual disease (MRD) status in patients with acute myeloid leukemia (AML), and further discusses novel techniques being evaluated to improve the accuracy of MRD assessment. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
